COVID 19COMMUNITYNCT06784739
COMMUNITY - the COVID-19 Immunity Study
An observational study of COVID 19 and Respiratory Synctial Virus, run by Danderyd Hospital at 2 sites in Sweden.
Trial summary
The principal aim of the COMMUNITY study is to investigate immune responses following SARS-CoV-2 infection and/or vaccination in healthcare workers and hospitalized COVID-19 patients. The study aims to enroll a total of 5,000 healthcare workers and 500 COVID-19 patients. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- COVID 19, Respiratory Synctial Virus, Influenza Virus
- What is being tested?
- Blood sampling, Mucosal sampling and PCR-test
- How many people
- 2,420 participants
- Where
- 2 sitesSweden
- Study dates
- 15 Apr 2020to Apr 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Danderyd Hospital employs approximately 4,500 healthcare workers. All HCWs are invited to participate in the study through information disseminated via the hospital intranet, email, and word of mouth.
Who may be able to join
- Health care workers: Employment at Danderyd hospital at time of enrollment
- COVID-19 patients: Admitted to Danderyd Hospital with confirmed SARS-CoV-2 infection at time of enrollment
Who cannot join
- No exclusion criteria
Trial locations and contacts
2 sites in 1 country.
Sweden2 sites
Danderyd hospital
Stockholm, 18288
Karolinska Institutet Danderyd Hospital
Stockholm, 18288
About this study
The principal aim of the COMMUNITY study is to investigate immune responses following SARS-CoV-2 infection and/or vaccination in healthcare workers and hospitalized COVID-19 patients. The study aims to enroll a total of 5,000 healthcare workers and 500 COVID-19 patients. All participants are enrolled at Danderyd Hospital in Stockholm, Sweden. Participants will be followed every four months with blood and mucosal sampling in addition to demographic and clinical data provided by the participants and from national registries.
Primary outcome:
Read more
- Antibody responses in blood and mucosa following SARS-CoV-2 infection and/or vaccination
Secondary outcomes:
- Cellular immune responses following SARS-CoV-2 infection and/or vaccination
- Antibody responses in blood and mucosa following following Influenza A/B infection and/or vaccination
- Antibody responses in blood and mucosa following following RSV A/B infection
Blood and mucosal samples are collected every 4 months and at tighter intervals in sub studies. PCR testing is conducted upon symptoms of respiratory infections and with regular intervals regardless of symptomatology in sub studies. Participants provide detailed demographic and clinical data through a smart phone application-based questionnaire. Data on infection and vaccination history is collected from national registries
Read the detailed description
The COMMUNITY study is designed to longitudinally follow healthcare workers and recovered COVID-19 patients to assess SARS-CoV-2 immune responses over time. Follow-ups are conducted every four months, including serum, PBMC, and mucosa (saliva and nasal secretions) samples. Sub studies with additional samplings and PCR screenings are conducted with regular intervals to assess vaccine responses and correlates to protection against infection.
Analyses include:
- Quantification and characterization of antibody responses
- Evaluation of T and B-cell responses
- RT-qPCR detection of viral infection
- Mucosal microbiome evaluation
Clinical and demographic data, including information on hospital workplace, exposure, immunosuppressive treatments or conditions, and results from SARS-CoV-2 Rapid Diagnostic Tests, are collected at each follow-up through a smartphone-based app system. Data on SARS-CoV-2 infections and vaccinations are obtained from national registries. In addition, data from home based PCR-screenings are continuously being monitored for SARS-CoV-2, Influenza and RSV infections.
All samples are stored in Biobank Sweden.
- Being tested
- Blood sampling, Mucosal sampling, PCR-test
- Keywords
- COVID-19, Mucosal immunity, Pandemic, Vaccination, Secretory IgA
- Medical subject headings
- COVID-19
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Blood samplingOther
Venous blood sampling
Mucosal samplingOther
Saliva and nasal secretions
PCR-testDiagnostic test
RT qPCR test to determine infection with SARS-CoV-2, Influenza A/B and/or RSV A/B.
| Study group | Role | What they receive |
|---|---|---|
| The COMMUNITY cohort - healthcare workers | 5000 healthcare workers employed at Danderyd Hospital at time of enrollment Receives: Other: Blood sampling; Other: Mucosal sampling; Diagnostic Test: PCR-test | |
| The COMMUNITY cohort - COVID-19 patients | 500 patients admitted to Danderyd Hospital with confirmed SARS-CoV-2 infection Receives: Other: Blood sampling; Other: Mucosal sampling; Diagnostic Test: PCR-test |
What is being measured
The primary outcome is the main question the study is designed to answer.
Antibody responses following SARS-CoV-2 infection and/or vaccination
Antigen-specific IgG and IgA responses in serum, saliva and nasal secretions (trajectories over time and correlates to protection against infection)
Measured: 2022-2026
Secondary outcomes (3)
Antibody responses following Influenza A/B infection and/or vaccination
Antigen-specific IgG and IgA responses in serum, saliva and nasal secretions (trajectories over time and correlates to protection against infection)
Measured: 2022-2026
Antibody responses following RSV infection
Antigen-specific IgG and IgA responses in serum, saliva and nasal secretions (trajectories over time and correlates to protection against infection)
Measured: 2020-2026
Cellular immune responses following SARS-CoV-2, Influenza A/B and RSV A/B infection and/or vaccination
T and B cell responses in blood
Measured: 2020-2026
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Jan 2025
- Study start15 Apr 2020
- Primary completionApr 2027 (estimated)
- Study completionApr 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (19)Papers the sponsor has linked to this study.
- Other trials for COVID 19Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 2,420 participants (actual)
Sponsor and investigators
- Lead sponsor
- Danderyd Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- Karolinska Institutet
- Responsible party
- Sponsor
- Investigators
- Charlotte Thålin, MD, PhD, Principal investigator, Department of Clinical Sciences, Karolinska Institutet Danderyd Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06784739
- Sponsor's protocol ID
- 2020-01653
- Other IDs
- 2020-01653
- Acronym
- COMMUNITY
- Status last verified
- Oct 2026
- First submitted
- 16 Jan 2025
- Last updated
- 7 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: Under consideration
Publications
Ng H, Havervall S, Rosell A, Aguilera K, Parv K, von Meijenfeldt FA, Lisman T, Mackman N, Thalin C, Phillipson M. Circulating Markers of Neutrophil Extracellular Traps Are of Prognostic Value in Patients With COVID-19. Arterioscler Thromb Vasc Biol. 2021 Feb;41(2):988-994. doi: 10.1161/ATVBAHA.120.315267. Epub 2020 Dec 3.
PubMed 33267662Sachetto ATA, Archibald SJ, Hisada Y, Rosell A, Havervall S, van Es N, Nieuwland R, Campbell RA, Middleton EA, Rondina MT, Thalin C, Mackman N. Tissue factor activity of small and large extracellular vesicles in different diseases. Res Pract Thromb Haemost. 2023 Mar;7(3):100124. doi: 10.1016/j.rpth.2023.100124. Epub 2023 Mar 15.
PubMed 37012986Monteil V, Eaton B, Postnikova E, Murphy M, Braunsfeld B, Crozier I, Kricek F, Niederhofer J, Schwarzbock A, Breid H, Devignot S, Klingstrom J, Thalin C, Kellner MJ, Christ W, Havervall S, Mereiter S, Knapp S, Sanchez Jimenez A, Bugajska-Schretter A, Dohnal A, Ruf C, Gugenberger R, Hagelkruys A, Montserrat N, Kozieradzki I, Hasan Ali O, Stadlmann J, Holbrook MR, Schmaljohn C, Oostenbrink C, Shoemaker RH, Mirazimi A, Wirnsberger G, Penninger JM. Clinical grade ACE2 as a universal agent to block SARS-CoV-2 variants. EMBO Mol Med. 2022 Aug 8;14(8):e15230. doi: 10.15252/emmm.202115230. Epub 2022 Jul 4.
PubMed 35781796Mravinacova S, Jonsson M, Christ W, Klingstrom J, Yousef J, Hellstrom C, Hedhammar M, Havervall S, Thalin C, Pin E, Tegel H, Nilsson P, Manberg A, Hober S. A cell-free high throughput assay for assessment of SARS-CoV-2 neutralizing antibodies. N Biotechnol. 2022 Jan 25;66:46-52. doi: 10.1016/j.nbt.2021.10.002. Epub 2021 Oct 7.
PubMed 34628049Havervall S, Jernbom Falk A, Klingstrom J, Ng H, Greilert-Norin N, Gabrielsson L, Salomonsson AC, Isaksson E, Rudberg AS, Hellstrom C, Andersson E, Olofsson J, Skoglund L, Yousef J, Pin E, Christ W, Olausson M, Hedhammar M, Tegel H, Mangsbo S, Phillipson M, Manberg A, Hober S, Nilsson P, Thalin C. SARS-CoV-2 induces a durable and antigen specific humoral immunity after asymptomatic to mild COVID-19 infection. PLoS One. 2022 Jan 12;17(1):e0262169. doi: 10.1371/journal.pone.0262169. eCollection 2022.
PubMed 35020778von Meijenfeldt FA, Havervall S, Adelmeijer J, Thalin C, Lisman T. Persistent endotheliopathy in the pathogenesis of long COVID syndrome: Comment from von Meijenfeldt et al. J Thromb Haemost. 2022 Jan;20(1):267-269. doi: 10.1111/jth.15580. Epub 2021 Nov 22. No abstract available.
PubMed 34731533Blom K, Bladh O, Havervall S, Marking U, Greilert Norin N, Alm JJ, Klingstrom J, Thalin C. Point prevalence of SARS-CoV-2 infection among healthcare workers in March and June 2023 in Sweden. Lancet Reg Health Eur. 2023 Aug 30;33:100725. doi: 10.1016/j.lanepe.2023.100725. eCollection 2023 Oct. No abstract available.
PubMed 37680234von Meijenfeldt FA, Havervall S, Adelmeijer J, Lundstrom A, Magnusson M, Mackman N, Thalin C, Lisman T. Sustained prothrombotic changes in COVID-19 patients 4 months after hospital discharge. Blood Adv. 2021 Feb 9;5(3):756-759. doi: 10.1182/bloodadvances.2020003968. No abstract available.
PubMed 33560386Havervall S, Rosell A, Phillipson M, Mangsbo SM, Nilsson P, Hober S, Thalin C. Symptoms and Functional Impairment Assessed 8 Months After Mild COVID-19 Among Health Care Workers. JAMA. 2021 May 18;325(19):2015-2016. doi: 10.1001/jama.2021.5612.
PubMed 33825846Blom K, Marking U, Havervall S, Norin NG, Gordon M, Garcia M, Tecleab T, Christ W, Forsell M, Phillipson M, Nilsson P, Mangsbo S, Hober S, Aberg M, Klingstrom J, Thalin C. Immune responses after omicron infection in triple-vaccinated health-care workers with and without previous SARS-CoV-2 infection. Lancet Infect Dis. 2022 Jul;22(7):943-945. doi: 10.1016/S1473-3099(22)00362-0. Epub 2022 Jun 9. No abstract available.
PubMed 35691303Havervall S, Marking U, Greilert-Norin N, Gordon M, Ng H, Christ W, Phillipson M, Nilsson P, Hober S, Blom K, Klingstrom J, Mangsbo S, Aberg M, Thalin C. Impact of SARS-CoV-2 infection on vaccine-induced immune responses over time. Clin Transl Immunology. 2022 Apr 18;11(4):e1388. doi: 10.1002/cti2.1388. eCollection 2022.
PubMed 35444806von Meijenfeldt FA, Havervall S, Adelmeijer J, Lundstrom A, Magnusson M, Mackman N, Thalin C, Lisman T. COVID-19 is Associated with an Acquired Factor XIII Deficiency. Thromb Haemost. 2021 Dec;121(12):1668-1669. doi: 10.1055/a-1450-8414. Epub 2021 May 5. No abstract available.
PubMed 33742434Blom K, Havervall S, Marking U, Norin NG, Bacchus P, Groenheit R, Brave A, Thalin C, Klingstrom J. Infection Rate of SARS-CoV-2 in Asymptomatic Healthcare Workers, Sweden, June 2022. Emerg Infect Dis. 2022 Oct;28(10):2119-2121. doi: 10.3201/eid2810.221093. Epub 2022 Aug 23.
PubMed 35997692Bladh O, Aguilera K, Marking U, Kihlgren M, Greilert Norin N, Smed-Sorensen A, Sallberg Chen M, Klingstrom J, Blom K, Russell MW, Havervall S, Thalin C, Aberg M. Comparison of SARS-CoV-2 spike-specific IgA and IgG in nasal secretions, saliva and serum. Front Immunol. 2024 Mar 15;15:1346749. doi: 10.3389/fimmu.2024.1346749. eCollection 2024.
PubMed 38558811Bladh O, Marking U, Havervall S, Norin NG, Aguilera K, Hober S, Smed-Sorensen A, Gordon M, Blom K, Aberg M, Klingstrom J, Thalin C. Mucosal immune responses following a fourth SARS-CoV-2 vaccine dose. Lancet Microbe. 2023 Jul;4(7):e488. doi: 10.1016/S2666-5247(23)00102-7. Epub 2023 Apr 20. No abstract available.
PubMed 37086736
Study at a glance
From the registry record, last updated by the sponsor on 7 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- COMMUNITY - the COVID-19 Immunity Study
- ClinicalTrials.gov ID
- NCT06784739
- Acronym / sponsor ID
- COMMUNITY / 2020-01653
- Keywords
- COVID-19, Mucosal immunity, Pandemic, Vaccination, Secretory IgA
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 2,420 participants (actual)
- Lead sponsor
- Danderyd HospitalUniversity, hospital or other
- Collaborators
- Karolinska Institutet
- Study start
- 15 Apr 2020 (actual)
- Primary completion
- Apr 2027 (estimated)
- Study completion
- Apr 2027 (estimated)
- First posted
- 20 Jan 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The principal aim of the COMMUNITY study is to investigate immune responses following SARS-CoV-2 infection and/or vaccination in healthcare workers and hospitalized COVID-19 patients. The study aims to enroll a total of 5,000 healthcare workers and 500 COVID-19 patients. All participants are enrolled at Danderyd Hospital in Stockholm, Sweden. Participants will be followed every four months with blood and mucosal sampling in addition to demographic and clinical data provided by the participants and from national registries.
Primary outcome:
- Antibody responses in blood and mucosa following SARS-CoV-2 infection and/or vaccination
Secondary outcomes:
- Cellular immune responses following SARS-CoV-2 infection and/or vaccination
- Antibody responses in blood and mucosa following following Influenza A/B infection and/or vaccination
- Antibody responses in blood and mucosa following following RSV A/B infection
Blood and mucosal samples are collected every 4 months and at tighter intervals in sub studies. PCR testing is conducted upon symptoms of respiratory infections and with regular intervals regardless of symptomatology in sub studies. Participants provide detailed demographic and clinical data through a smart phone application-based questionnaire. Data on infection and vaccination history is collected from national registries
Detailed description
The COMMUNITY study is designed to longitudinally follow healthcare workers and recovered COVID-19 patients to assess SARS-CoV-2 immune responses over time. Follow-ups are conducted every four months, including serum, PBMC, and mucosa (saliva and nasal secretions) samples. Sub studies with additional samplings and PCR screenings are conducted with regular intervals to assess vaccine responses and correlates to protection against infection.
Analyses include:
- Quantification and characterization of antibody responses
- Evaluation of T and B-cell responses
- RT-qPCR detection of viral infection
- Mucosal microbiome evaluation
Clinical and demographic data, including information on hospital workplace, exposure, immunosuppressive treatments or conditions, and results from SARS-CoV-2 Rapid Diagnostic Tests, are collected at each follow-up through a smartphone-based app system. Data on SARS-CoV-2 infections and vaccinations are obtained from national registries. In addition, data from home based PCR-screenings are continuously being monitored for SARS-CoV-2, Influenza and RSV infections.
All samples are stored in Biobank Sweden.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| The COMMUNITY cohort - healthcare workers | – | Other: Blood sampling, Other: Mucosal sampling, Diagnostic Test: PCR-test5000 healthcare workers employed at Danderyd Hospital at time of enrollment |
| The COMMUNITY cohort - COVID-19 patients | – | Other: Blood sampling, Other: Mucosal sampling, Diagnostic Test: PCR-test500 patients admitted to Danderyd Hospital with confirmed SARS-CoV-2 infection |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Danderyd Hospital employs approximately 4,500 healthcare workers. All HCWs are invited to participate in the study through information disseminated via the hospital intranet, email, and word of mouth.
Key inclusion criteria (2 listed)
- Health care workers: Employment at Danderyd hospital at time of enrollment
- COVID-19 patients: Admitted to Danderyd Hospital with confirmed SARS-CoV-2 infection at time of enrollment
Key exclusion criteria (1 listed)
- No exclusion criteria
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Blood samplingVenous blood sampling | Other | The COMMUNITY cohort - COVID-19 patients, The COMMUNITY cohort - healthcare workers |
| Mucosal samplingSaliva and nasal secretions | Other | The COMMUNITY cohort - COVID-19 patients, The COMMUNITY cohort - healthcare workers |
| PCR-testRT qPCR test to determine infection with SARS-CoV-2, Influenza A/B and/or RSV A/B. | Diagnostic test | The COMMUNITY cohort - COVID-19 patients, The COMMUNITY cohort - healthcare workers |
Primary outcome
Antibody responses following SARS-CoV-2 infection and/or vaccination
Time frame: 2022-2026
Antigen-specific IgG and IgA responses in serum, saliva and nasal secretions (trajectories over time and correlates to protection against infection)
3 secondary outcomes
Antibody responses following Influenza A/B infection and/or vaccination
Time frame: 2022-2026
Antibody responses following RSV infection
Time frame: 2020-2026
Cellular immune responses following SARS-CoV-2, Influenza A/B and RSV A/B infection and/or vaccination
Time frame: 2020-2026
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Oct 2026.
- Background: PubMed 33267662Ng H, Havervall S, Rosell A, Aguilera K, Parv K, von Meijenfeldt FA, Lisman T, Mackman N, Thalin C, Phillipson M. Circulating Markers of Neutrophil Extracellular Traps Are of Prognostic Value in Patients With COVID-19. Arterioscler Thromb Vasc Biol. 2021 Feb;41(2):988-994. doi: 10.1161/ATVBAHA.120.315267. Epub 2020 Dec 3.
- Background: PubMed 37012986Sachetto ATA, Archibald SJ, Hisada Y, Rosell A, Havervall S, van Es N, Nieuwland R, Campbell RA, Middleton EA, Rondina MT, Thalin C, Mackman N. Tissue factor activity of small and large extracellular vesicles in different diseases. Res Pract Thromb Haemost. 2023 Mar;7(3):100124. doi: 10.1016/j.rpth.2023.100124. Epub 2023 Mar 15.
- Background: PubMed 35781796Monteil V, Eaton B, Postnikova E, Murphy M, Braunsfeld B, Crozier I, Kricek F, Niederhofer J, Schwarzbock A, Breid H, Devignot S, Klingstrom J, Thalin C, Kellner MJ, Christ W, Havervall S, Mereiter S, Knapp S, Sanchez Jimenez A, Bugajska-Schretter A, Dohnal A, Ruf C, Gugenberger R, Hagelkruys A, Montserrat N, Kozieradzki I, Hasan Ali O, Stadlmann J, Holbrook MR, Schmaljohn C, Oostenbrink C, Shoemaker RH, Mirazimi A, Wirnsberger G, Penninger JM. Clinical grade ACE2 as a universal agent to block SARS-CoV-2 variants. EMBO Mol Med. 2022 Aug 8;14(8):e15230. doi: 10.15252/emmm.202115230. Epub 2022 Jul 4.
- Background: PubMed 34628049Mravinacova S, Jonsson M, Christ W, Klingstrom J, Yousef J, Hellstrom C, Hedhammar M, Havervall S, Thalin C, Pin E, Tegel H, Nilsson P, Manberg A, Hober S. A cell-free high throughput assay for assessment of SARS-CoV-2 neutralizing antibodies. N Biotechnol. 2022 Jan 25;66:46-52. doi: 10.1016/j.nbt.2021.10.002. Epub 2021 Oct 7.
- Results publication: PubMed 35020778Havervall S, Jernbom Falk A, Klingstrom J, Ng H, Greilert-Norin N, Gabrielsson L, Salomonsson AC, Isaksson E, Rudberg AS, Hellstrom C, Andersson E, Olofsson J, Skoglund L, Yousef J, Pin E, Christ W, Olausson M, Hedhammar M, Tegel H, Mangsbo S, Phillipson M, Manberg A, Hober S, Nilsson P, Thalin C. SARS-CoV-2 induces a durable and antigen specific humoral immunity after asymptomatic to mild COVID-19 infection. PLoS One. 2022 Jan 12;17(1):e0262169. doi: 10.1371/journal.pone.0262169. eCollection 2022.
- Results publication: PubMed 34731533von Meijenfeldt FA, Havervall S, Adelmeijer J, Thalin C, Lisman T. Persistent endotheliopathy in the pathogenesis of long COVID syndrome: Comment from von Meijenfeldt et al. J Thromb Haemost. 2022 Jan;20(1):267-269. doi: 10.1111/jth.15580. Epub 2021 Nov 22. No abstract available.
- Results publication: PubMed 37680234Blom K, Bladh O, Havervall S, Marking U, Greilert Norin N, Alm JJ, Klingstrom J, Thalin C. Point prevalence of SARS-CoV-2 infection among healthcare workers in March and June 2023 in Sweden. Lancet Reg Health Eur. 2023 Aug 30;33:100725. doi: 10.1016/j.lanepe.2023.100725. eCollection 2023 Oct. No abstract available.
- Results publication: PubMed 33560386von Meijenfeldt FA, Havervall S, Adelmeijer J, Lundstrom A, Magnusson M, Mackman N, Thalin C, Lisman T. Sustained prothrombotic changes in COVID-19 patients 4 months after hospital discharge. Blood Adv. 2021 Feb 9;5(3):756-759. doi: 10.1182/bloodadvances.2020003968. No abstract available.
- Results publication: PubMed 33825846Havervall S, Rosell A, Phillipson M, Mangsbo SM, Nilsson P, Hober S, Thalin C. Symptoms and Functional Impairment Assessed 8 Months After Mild COVID-19 Among Health Care Workers. JAMA. 2021 May 18;325(19):2015-2016. doi: 10.1001/jama.2021.5612.
- Results publication: PubMed 35691303Blom K, Marking U, Havervall S, Norin NG, Gordon M, Garcia M, Tecleab T, Christ W, Forsell M, Phillipson M, Nilsson P, Mangsbo S, Hober S, Aberg M, Klingstrom J, Thalin C. Immune responses after omicron infection in triple-vaccinated health-care workers with and without previous SARS-CoV-2 infection. Lancet Infect Dis. 2022 Jul;22(7):943-945. doi: 10.1016/S1473-3099(22)00362-0. Epub 2022 Jun 9. No abstract available.
- Results publication: PubMed 35444806Havervall S, Marking U, Greilert-Norin N, Gordon M, Ng H, Christ W, Phillipson M, Nilsson P, Hober S, Blom K, Klingstrom J, Mangsbo S, Aberg M, Thalin C. Impact of SARS-CoV-2 infection on vaccine-induced immune responses over time. Clin Transl Immunology. 2022 Apr 18;11(4):e1388. doi: 10.1002/cti2.1388. eCollection 2022.
- Results publication: PubMed 33742434von Meijenfeldt FA, Havervall S, Adelmeijer J, Lundstrom A, Magnusson M, Mackman N, Thalin C, Lisman T. COVID-19 is Associated with an Acquired Factor XIII Deficiency. Thromb Haemost. 2021 Dec;121(12):1668-1669. doi: 10.1055/a-1450-8414. Epub 2021 May 5. No abstract available.
- Charlotte Thålin Group at KILink provided by the sponsor.
- Individual participant dataSharing planned: Undecided. Under consideration
Related trials for COVID 19
RecruitingPhase 3
A Study of Secutrelvir in Participants With Coronavirus Disease 2019 (COVID-19) Who Are at High Risk for Progression to Severe Disease
SARS-CoV-2
RecruitingObservational study
Viral Infections in Healthy and Immunocompromised Hosts
Anogenital Herpes, COVID-19
Active, not recruiting
Motivational Interviewing Intervention for Families With Overweight and Obesity
Obesity & Overweight
Active, not recruiting
Lupus Education Alliance Program
Systemic Lupus Erythematosus, COVID-19
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Charlotte Thålin, MD, PhD principal investigator
Department of Clinical Sciences, Karolinska Institutet Danderyd Hospital
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of COVID 19 and Respiratory Synctial Virus, run by Danderyd Hospital at 2 sites in Sweden.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 7 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Sweden. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Antibody responses following SARS-CoV-2 infection and/or vaccination (time frame: 2022-2026). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06784739, which also lists 19 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Oct 2026.